NOVADAQ Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company's SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The SPY Fluorescence Imaging platform can be used to develop imaging devices specifically designed to meet the needs of different surgeons and other healthcare providers and the specialty procedures they perform. SPY images enable physicians treating life-threatening illnesses, such as breast, head and neck, colon, complex hernias, diabetes and certain cardiovascular diseases.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:NVDQ
CUSIPN/A
Phone+1-905-6293822
Debt
Debt-to-Equity Ratio0.11
Current Ratio3.49
Quick Ratio3.30
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-66.61%
Return on Equity-51.89%
Return on Assets-40.92%
Miscellaneous
Employees416
Outstanding Shares57,820,000
Novadaq Technologies (NASDAQ:NVDQ) Frequently Asked Questions
What is Novadaq Technologies' stock symbol?
Novadaq Technologies trades on the NASDAQ under the ticker symbol "NVDQ."
How were Novadaq Technologies' earnings last quarter?
Novadaq Technologies Inc. (NASDAQ:NVDQ) released its quarterly earnings data on Wednesday, May, 3rd. The medical research company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The medical research company earned $21.08 million during the quarter, compared to analyst estimates of $20.12 million. Novadaq Technologies had a negative net margin of 66.61% and a negative return on equity of 51.89%. View Novadaq Technologies' Earnings History.
What price target have analysts set for NVDQ?
4 Wall Street analysts have issued twelve-month price objectives for Novadaq Technologies' shares. Their forecasts range from $11.75 to $11.75. On average, they expect Novadaq Technologies' stock price to reach $11.75 in the next year. View Analyst Ratings for Novadaq Technologies.
What are Wall Street analysts saying about Novadaq Technologies stock?
Here are some recent quotes from research analysts about Novadaq Technologies stock:
- 1. According to Zacks Investment Research, "Novadaq Technologies Inc. develops, manufactures and markets real-time fluorescence imaging products for use in the operating room and other clinical settings. The company's key markets include plastic reconstructive, gastrointestinal, cardiac and general surgery. It provides SPY imaging systems which enables surgeons to the visualize blood flow in vessels, co-joined vessels and micro-vessels. Novadaq Technologies Inc. is headquartered in Mississauga, Canada. " (8/18/2017)
- 2. Northland Securities analysts commented, "We feel somewhat vindicated that the core biz was not doing OK, forward estimates were out of whack, and the bullish sell-side commentary at large was not based on a true understanding of the science…or ground fundamentals…Yes, it is water under the bridge now…..but sometimes postmortems are necessary." (8/14/2017)
Who are Novadaq Technologies' key executives?
Novadaq Technologies' management team includes the folowing people:
- William A. MacKinnon, Chairman of the Board
- Rick Mangat Ph.D., President, Chief Executive Officer
- , Bio & Compensation -
- Roger Deck, Chief Financial Officer
- , Bio & Compensation -
- Lori Swalm, Vice President of Marketing
- , Bio & Compensation -
- Derrick Guo, General Counsel, Corporate Secretary
- , Bio & Compensation -
- Anthony F. Griffiths, Lead Independent Director
- Lisa N. Colleran, Director
- Karen A. Licitra, Director
- , Bio & Compensation -
- Patrice E. Merrin, Independent Director
- Thomas G. Wellner, Independent Director
Has Novadaq Technologies been receiving favorable news coverage?
News coverage about NVDQ stock has been trending somewhat positive on Friday, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novadaq Technologies earned a media sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 45.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Novadaq Technologies?
Shares of NVDQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novadaq Technologies' stock price today?
One share of NVDQ stock can currently be purchased for approximately $11.75.
How can I contact Novadaq Technologies?
Novadaq Technologies' mailing address is 5090 Explorer Dr Suite 202, MISSISSAUGA, ON L4W 4T9, Canada. The medical research company can be reached via phone at +1-905-6293822.
MarketBeat Community Rating for Novadaq Technologies (NVDQ)
MarketBeat's community ratings are surveys of what our community members think about Novadaq Technologies and other stocks. Vote "Outperform" if you believe NVDQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVDQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
